
Grace L Su

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6559551/publications.pdf Version: 2024-02-01



CRACE | SU

#	Article	IF	CITATIONS
1	Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. Journal of Hepatology, 2022, 76, 588-599.	1.8	164
2	A correction score to compare aortic calcification in contrast enhanced and non-contrast measurements from computed tomography scans. Clinical Imaging, 2022, 83, 51-55.	0.8	2
3	Muscle Mass Affects Paclitaxel Systemic Exposure and May Inform Personalized Paclitaxel Dosing. British Journal of Clinical Pharmacology, 2022, , .	1.1	2
4	Healthy US population reference values for CT visceral fat measurements and the impact of IV contrast, HU range, and spinal levels. Scientific Reports, 2022, 12, 2374.	1.6	9
5	Systematic review: development of a consensus code set to identify cirrhosis in electronic health records. Alimentary Pharmacology and Therapeutics, 2022, 55, 645-657.	1.9	20
6	AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology, 2022, 162, 920-934.	0.6	81
7	Metabolic abnormalities, liver and body fat in American <i>versus</i> Chinese patients with nonâ€elcoholic fatty liver disease. JGH Open, 2022, 6, 519-530.	0.7	2
8	The psoas muscle index distribution and influence of outcomes in an Asian adult trauma population: an alternative indicator for sarcopenia of acute diseases. European Journal of Trauma and Emergency Surgery, 2021, 47, 1787-1795.	0.8	16
9	The Use of Readily Available Longitudinal Data to Predict the Likelihood of Surgery in Crohn Disease. Inflammatory Bowel Diseases, 2021, 27, 1328-1334.	0.9	6
10	Predicting outcomes of abdominal surgical emergencies in the elderly population using a CT muscle gauge. Aging Clinical and Experimental Research, 2021, 33, 2479-2490.	1.4	7
11	Reply. Gastroenterology, 2021, 160, 2633-2635.	0.6	0
12	Automated Measurements of Body Composition in Abdominal CT Scans Using Artificial Intelligence Can Predict Mortality in Patients With Cirrhosis. Hepatology Communications, 2021, 5, 1901-1910.	2.0	12
13	Oral simethicone tablets with PEGâ€ELS splitâ€prep reduces frequency of inadequate bowel cleansing and decreases bubbles. GastroHep, 2021, 3, 254-260.	0.3	0
14	Does a "Cushion Effect―Really Exist? A Morphomic Analysis of Vulnerable Road Users with Serious Blunt Abdominal Injury. Healthcare (Switzerland), 2021, 9, 1006.	1.0	2
15	Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2021, 54, 890-901.	1.9	65
16	AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology, 2021, 161, 1615-1627.e1.	0.6	43
17	Optimal body size adjustment of L3 CT skeletal muscle area for sarcopenia assessment. Scientific Reports, 2021, 11, 279.	1.6	30
18	Adapted time-varying covariates Cox model for predicting future cirrhosis development performs well in a large hepatitis C cohort. BMC Medical Informatics and Decision Making, 2021, 21, 347.	1.5	1

#	Article	IF	CITATIONS
19	Assessing Small Bowel Stricturing and Morphology in Crohn's Disease Using Semi-automated Image Analysis. Inflammatory Bowel Diseases, 2020, 26, 734-742.	0.9	39
20	Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients. Digestive Diseases and Sciences, 2020, 65, 2130-2139.	1.1	7
21	Body composition predicts mortality and decompensation in compensated cirrhosis patients: A prospective cohort study. JHEP Reports, 2020, 2, 100061.	2.6	38
22	Spotlight: Probiotics Guidelines. Gastroenterology, 2020, 159, 707.	0.6	3
23	Automated Measurements of Muscle Mass Using Deep Learning Can Predict Clinical Outcomes in Patients With Liver Disease. American Journal of Gastroenterology, 2020, 115, 1210-1216.	0.2	16
24	Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. JAMA Network Open, 2020, 3, e2015626.	2.8	75
25	Eliciting patient views on the allocation of limited healthcare resources: a deliberation on hepatitis C treatment in the Veterans Health Administration. BMC Health Services Research, 2020, 20, 369.	0.9	4
26	AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Annals of Allergy, Asthma and Immunology, 2020, 124, 416-423.	0.5	41
27	Technical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. Gastroenterology, 2020, 158, 1789-1810.e15.	0.6	83
28	AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology, 2020, 159, 697-705.	0.6	209
29	Comparison of Body Size, Morphomics, and Kidney Function as Covariates of Highâ€Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma. Pharmacotherapy, 2020, 40, 308-319.	1.2	12
30	AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology, 2020, 158, 1450-1461.	0.6	355
31	AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology, 2020, 158, 1776-1786.	0.6	188
32	Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters. Annals of Allergy, Asthma and Immunology, 2020, 124, 424-440.e17.	0.5	49
33	Machine learning methods to predict presence of intestine damage in patients with Crohn's disease. , 2020, , .		4
34	Morphomic calcification score from clinical CT scans: A proxy for coronary artery calcium. Clinical Imaging, 2020, 66, 57-63.	0.8	3
35	Abstract 14101: A Correction Score for Comparison of Aortic Calcification in Post-contrast and Non-contrast Measurements From Computed Tomography Scans. Circulation, 2020, 142, .	1.6	1
36	Bedside Measures of Frailty and Cognitive Function Correlate with Sarcopenia in Patients with Cirrhosis. Digestive Diseases and Sciences, 2019, 64, 3652-3659.	1.1	30

#	Article	IF	CITATIONS
37	Electronic Consultations: Delivering Specialty Care Anywhere. Hepatology Communications, 2019, 3, 1171-1173.	2.0	0
38	Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis. Hepatology Communications, 2019, 3, 1585-1597.	2.0	8
39	AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology, 2019, 156, 748-764.	0.6	194
40	Machine learning models to predict disease progression among veterans with hepatitis C virus. PLoS ONE, 2019, 14, e0208141.	1.1	59
41	Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	5
42	Reply. Hepatology, 2018, 67, 1637-1638.	3.6	0
43	Reply. Hepatology, 2018, 67, 1636-1636.	3.6	0
44	Quantifying Sarcopenia Reference Values Using Lumbar and Thoracic Muscle Areas in a Healthy Population. Journal of Nutrition, Health and Aging, 2018, 22, 180-185.	1.5	73
45	A risk score to predict the development of hepatic encephalopathy in a populationâ€based cohort of patients with cirrhosis. Hepatology, 2018, 68, 1498-1507.	3.6	60
46	Morphomic Malnutrition Score: A Standardized Screening Tool for Severe Malnutrition in Adults. Journal of Parenteral and Enteral Nutrition, 2018, 42, 1263-1271.	1.3	9
47	Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Scientific Reports, 2018, 8, 11369.	1.6	286
48	Virtual Consultations Through the Veterans Administration SCANâ€ECHO Project Improves Survival for Veterans With Liver Disease. Hepatology, 2018, 68, 2317-2324.	3.6	61
49	Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Cancer Research and Treatment, 2018, 50, 530-537.	1.3	23
50	Introducing the AASLD president: Anna S.F. Lok. Hepatology, 2017, 65, 1084-1087.	3.6	0
51	Morphomics-Based Risk Stratification Model Predicts Complications after Pancreaticoduodenectomy for Pancreatic Cystic Neoplasms. Gastroenterology, 2017, 152, S133.	0.6	0
52	Relationships of Vancomycin Pharmacokinetics to Body Size and Composition Using a Novel Pharmacomorphomic Approach Based on Medical Imaging. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	6
53	Specialty Care Access Network-Extension of Community Healthcare Outcomes Model Program for Liver Disease Improves Specialty Care Access. Digestive Diseases and Sciences, 2017, 62, 3344-3349.	1.1	16
54	Falls risk assessments: Too much, too little or just right?. Applied Nursing Research, 2017, 36, 135-136.	1.0	0

#	Article	IF	CITATIONS
55	Validation of the Total Visual Acuity Extraction Algorithm (TOVA) for Automated Extraction of Visual Acuity Data From Free Text, Unstructured Clinical Records. Translational Vision Science and Technology, 2017, 6, 2.	1.1	15
56	Comparison of retina specialist preferences regarding spectral-domain and swept-source optical coherence tomography angiography. Clinical Ophthalmology, 2017, Volume 11, 889-895.	0.9	6
57	Disparities in delivery of ophthalmic care; An exploration of public Medicare data. PLoS ONE, 2017, 12, e0182598.	1.1	25
58	Apyrase Elicits Host Antimicrobial Responses and Resolves Infection in Burns. Journal of Burn Care and Research, 2016, 37, e501-e507.	0.2	2
59	Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 2016, 7, e172.	1.3	18
60	Does Karnofsky Performance Status of Patients With Cirrhosis onÂthe Transplant Waitlist Meet the Eyeball Test?. Clinical Gastroenterology and Hepatology, 2016, 14, 1196-1198.	2.4	14
61	Access to Subspecialty Care And Survival Among Patients With Liver Disease. American Journal of Gastroenterology, 2016, 111, 838-844.	0.2	22
62	Metabolic Bone Disease in Primary Biliary Cirrhosis. Gastroenterology Clinics of North America, 2016, 45, 333-343.	1.0	20
63	Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients. Liver Transplantation, 2016, 22, 1092-1098.	1.3	42
64	Limitations of the barcelona clinic liver cancer staging system with a focus on transarterial chemoembolization as a key modality for treatment of hepatocellular carcinoma. Clinical Liver Disease, 2016, 7, 32-35.	1.0	9
65	Reply to Body Fat Composition Predicts Infectious Complications After Bowel Resection in Crohn's Disease. Inflammatory Bowel Diseases, 2015, 21, E19-E20.	0.9	29
66	Influence of Lipopolysaccharide-Binding Protein on Pulmonary Inflammation in Gram-Negative Pneumonia. Shock, 2015, 43, 612-619.	1.0	14
67	Body Fat Composition Assessment Using Analytic Morphomics Predicts Infectious Complications After Bowel Resection in Crohn's Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	28
68	Use of Analytic Morphomics of Liver, Spleen, and Body Composition to Identify Patients at Risk for Cirrhosis. Clinical Gastroenterology and Hepatology, 2015, 13, 360-368.e5.	2.4	29
69	Sa1857 Analytic Morphomics Predicts Overall Survival in Patients With Hepatocellular Carcinoma. Gastroenterology, 2015, 148, S-1026.	0.6	1
70	Access to Outpatient Specialty Care. American Journal of Medical Quality, 2015, 30, 88-90.	0.2	37
71	Analytic morphomics identifies predictors of newâ€onset diabetes after liver transplantation. Clinical Transplantation, 2015, 29, 458-464.	0.8	11
72	Visceral adiposity is negatively associated with bone density and muscle attenuation. American Journal of Clinical Nutrition, 2015, 101, 337-343.	2.2	98

#	Article	IF	CITATIONS
73	Analytic Morphomics Accurately Distinguishes Serous and Mucinous Cystic Neoplasms. American Journal of Gastroenterology, 2015, 110, S12.	0.2	0
74	Predictors of Mortality in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Digestive Diseases and Sciences, 2014, 59, 2821-2825.	1.1	18
75	The Educational Impact of the Specialty Care Access Network–Extension of Community Healthcare Outcomes Program. Telemedicine Journal and E-Health, 2014, 20, 1004-1008.	1.6	31
76	The macrophage LBP gene is an LXR target that promotes macrophage survival and atherosclerosis. Journal of Lipid Research, 2014, 55, 1120-1130.	2.0	21
77	Adenosine Triphosphate Hydrolysis Reduces Neutrophil Infiltration and Necrosis in Partial-Thickness Scald Burns in Mice. Journal of Burn Care and Research, 2014, 35, 54-61.	0.2	17
78	Quantitative Detection of Cirrhosis: Towards the Development of Computer-Assisted Detection Method. Journal of Digital Imaging, 2014, 27, 601-609.	1.6	2
79	Early detection of burn induced heterotopic ossification using transcutaneous Raman spectroscopy. Bone, 2013, 54, 28-34.	1.4	78
80	Obesity and IBD: Are We Tipping the Scales Toward an Epidemic?. Gastroenterology, 2013, 145, 478-479.	0.6	4
81	The quantification of liver anatomical changes and assessment of occupant liver injury patterns. Stapp Car Crash Journal, 2013, 57, 267-83.	1.1	3
82	Lipopolysaccharide binding protein inhibitory peptide alters hepatic inflammatory response post-hemorrhagic shock. Innate Immunity, 2012, 18, 866-875.	1.1	8
83	<scp>YKL</scp> â€40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver International, 2012, 32, 665-674.	1.9	21
84	Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 793-799.	1.1	227
85	Lipopolysaccharide Binding Protein Is Down-Regulated During Acute Liver Failure. Digestive Diseases and Sciences, 2012, 57, 918-924.	1.1	4
86	Development of a quantitative method for the diagnosis of cirrhosis. Scandinavian Journal of Gastroenterology, 2011, 46, 1468-1477.	0.6	15
87	Burn-induced Heart Failure: Lipopolysaccharide Binding Protein Improves Burn and Endotoxin-Induced Cardiac Contractility Deficits. Journal of Surgical Research, 2011, 165, 128-135.	0.8	15
88	Patient Involvement in Healthcare is Associated With Higher Rates of Surveillance for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2011, 45, 727-732.	1.1	83
89	Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut, 2010, 59, 1401-1409.	6.1	92
90	Lipopolysaccharide binding protein inhibitory peptide protects against acetaminophen-induced hepatotoxicity. American Journal of Physiology - Renal Physiology, 2010, 299, G1319-G1325.	1.6	18

#	Article	IF	CITATIONS
91	LPS-binding protein mediates LPS-induced liver injury and mortality in the setting of biliary obstruction. American Journal of Physiology - Renal Physiology, 2009, 296, G45-G54.	1.6	30
92	Local wound p38 MAPK inhibition attenuates burn-induced cardiac dysfunction. Surgery, 2009, 146, 775-786.	1.0	13
93	Serum Fibrosis Marker Levels Decrease After Successful Antiviral Treatment in Chronic Hepatitis C Patients With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2009, 7, 219-226.	2.4	42
94	Pregnancy and liver disease. Current Gastroenterology Reports, 2008, 10, 15-21.	1.1	5
95	Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology, 2008, 47, 789-798.	3.6	155
96	C5a-Blockade Improves Burn-Induced Cardiac Dysfunction. Journal of Immunology, 2007, 178, 7902-7910.	0.4	43
97	Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: A comparison of AFP, DCP, and AFP-L31. Cancer Biomarkers, 2007, 3, 79-87.	0.8	131
98	Attenuating burn wound inflammation improves pulmonary function and survival in a burn-pneumonia model. Critical Care Medicine, 2007, 35, 2139-2144.	0.4	24
99	Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transplantation, 2007, 13, 1100-1108.	1.3	92
100	Topical p38 MAPK inhibition reduces bacterial growth in an in vivo burn wound model. Surgery, 2007, 142, 86-93.	1.0	21
101	XIAP Is a Copper Binding Protein Deregulated in Wilson's Disease and Other Copper Toxicosis Disorders. Molecular Cell, 2006, 21, 775-785.	4.5	157
102	TOPICAL p38MAPK INHIBITION REDUCES DERMAL INFLAMMATION AND EPITHELIAL APOPTOSIS IN BURN WOUNDS. Shock, 2006, 26, 201-209.	1.0	64
103	SYSTEMIC C5a INHIBITION REDUCES PITUITARY INFLAMMATION AND RESTORES GROWTH HORMONE SECRETION IN SEPSIS. Shock, 2006, 26, 13.	1.0	0
104	Gene Therapy with Lipopolysaccharide Binding Protein for Gram-Negative Pneumonia: Respiratory Physiology. Journal of Trauma, 2006, 61, 598-606.	2.3	12
105	CARDIOMYOCYTE FUNCTION AFTER BURN INJURY AND LIPOPOLYSACCHARIDE EXPOSURE: SINGLE-CELL CONTRACTION ANALYSIS AND CYTOKINE SECRETION PROFILE. Shock, 2006, 25, 176-183.	1.0	40
106	Immune thrombocytopenic purpura following liver transplantation: A case series and review of the literature. Liver Transplantation, 2006, 12, 781-791.	1.3	30
107	HOW MUCH CROSSTALK EXISTS BETWEEN THE COMPLEMENT AND TLR SYSTEMS IN CARDIOMYOCYTES FOLLOWING BURN INJURY?. Shock, 2006, 25, 89.	1.0	0
108	Attenuating Burn Wound Inflammatory Signaling Reduces Systemic Inflammation and Acute Lung Injury. Journal of Immunology, 2006, 177, 8065-8071.	0.4	70

#	Article	IF	CITATIONS
109	An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. Journal of Experimental Medicine, 2006, 203, 53-61.	4.2	166
110	HEPATOCYTES ENHANCE EFFECTS OF LIPOPOLYSACCHARIDE ON LIVER NONPARENCHYMAL CELLS THROUGH CLOSE CELL INTERACTIONS. Shock, 2005, 23, 453-458.	1.0	34
111	Improved Survival in Mice Given Systemic Gene Therapy in a Gram Negative Pneumonia Model. Journal of Trauma, 2005, 58, 1110-1118.	2.3	10
112	Altered Kupffer cell function in biliary obstruction. Surgery, 2005, 138, 236-245.	1.0	37
113	Lipopolysaccharide-binding protein modulates acetaminophen-induced liver injury in mice. Hepatology, 2005, 41, 187-195.	3.6	50
114	Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort. Hepatology, 2005, 41, 707-715.	3.6	579
115	Reply:. Hepatology, 2005, 42, 739-740.	3.6	4
116	Hepatitis C in pregnancy. Current Gastroenterology Reports, 2005, 7, 45-49.	1.1	8
117	Burn wounds infected with Pseudomonas aeruginosa triggers weight loss in rats. BMC Surgery, 2005, 5, 19.	0.6	9
118	Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. Journal of Hepatology, 2005, 42, 218-224.	1.8	461
119	Impaired Hepatocyte Regeneration in Toll-Like Receptor 4 Mutant Mice. Digestive Diseases and Sciences, 2004, 49, 843-849.	1.1	19
120	Effectiveness of interferon ?-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clinical Gastroenterology and Hepatology, 2004, 2, 425-431.	2.4	23
121	Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology, 2003, 37, 1114-1121.	3.6	331
122	Adenoviral gene transfer of lipopolysaccharide binding protein (LBP) results in increased acetaminophen-induced hepatotoxicity. Gastroenterology, 2003, 124, A689-A690.	0.6	3
123	Protegrin-1 increases bacterial clearance in sepsis but decreases survival. Critical Care Medicine, 2003, 31, 221-226.	0.4	155
124	Activation of human and mouse Kupffer cells by lipopolysaccharide is mediated by CD14. American Journal of Physiology - Renal Physiology, 2002, 283, G640-G645.	1.6	71
125	Activity of Novispirin G10 against Pseudomonas aeruginosa In Vitro and in Infected Burns. Antimicrobial Agents and Chemotherapy, 2002, 46, 1837-1844.	1.4	94
126	Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. American Journal of Physiology - Renal Physiology, 2002, 283, G256-G265.	1.6	400

#	Article	IF	CITATIONS
127	An Essential Role for Lipopolysaccharide-Binding Protein in Pulmonary Innate Immune Responses. Shock, 2002, 18, 248-254.	1.0	50
128	Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. Journal of Hepatology, 2002, 36, 401-407.	1.8	109
129	Thermal injury induces expression of CD14 in human skin. Burns, 2002, 28, 223-230.	1.1	16
130	NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States. Hepatology, 2002, 36, 1349-1354.	3.6	296
131	Pathogenesis of Alcoholic Liver Disease-Recent Advances. Alcoholism: Clinical and Experimental Research, 2002, 26, 731-736.	1.4	27
132	NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology, 2002, 36, 1349-1354.	3.6	413
133	Pathogenesis of Alcoholic Liver Disease???Recent Advances. Alcoholism: Clinical and Experimental Research, 2002, 26, 731-736.	1.4	0
134	Kupffer cell activation by LPS is mediated via LPS binding protein and CD14. Gastroenterology, 2001, 120, A27.	0.6	0
135	Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines. American Journal of Physiology - Renal Physiology, 2001, 281, G1348-G1356.	1.6	122
136	Protegrin-1 enhances bacterial killing in thermally injured skin. Critical Care Medicine, 2001, 29, 1431-1437.	0.4	43
137	FEASIBILITY OF BIOLISTIC GENE THERAPY IN BURNS. Shock, 2001, 15, 272-277.	1.0	23
138	Outcome of liver transplantation for hepatitis B: Report of a single center's experience. Liver Transplantation, 2001, 7, 724-731.	1.3	13
139	Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. American Journal of Gastroenterology, 2001, 96, 2737-2744.	0.2	93
140	Skin Lipopolysaccharide-Binding Protein and IL-1β Production After Thermal Injury. Journal of Burn Care and Research, 2000, 21, 345-352.	1.7	10
141	Kupffer cell activation by lipopolysaccharide in rats: Role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology, 2000, 31, 932-936.	3.6	237
142	Mechanism of the alcohol cyclic pattern: role of the hypothalamic-pituitary-thyroid axis. American Journal of Physiology - Renal Physiology, 2000, 279, G118-G125.	1.6	44
143	Lipopolysaccharide-Binding Protein Accelerates and Augments Escherichia coli Phagocytosis by Alveolar Macrophages. Journal of Surgical Research, 2000, 94, 159-166.	0.8	28
144	The biological activity of lipopolyscaccharide binding protein is determined by concentration. Gastroenterology, 2000, 118, A1021.	0.6	0

#	Article	IF	CITATIONS
145	Skin lipopolysaccharide-binding protein and IL-1[beta] production after thermal injury. Journal of Burn Care and Research, 2000, 021, 345-352.	1.7	4
146	Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat. Hepatology, 1999, 30, 934-943.	3.6	202
147	CD14 expression and production by human hepatocytes. Journal of Hepatology, 1999, 31, 435-442.	1.8	82
148	Recombinant rat LBP accelerates LPS-induced Kupffer cell activation. Gastroenterology, 1998, 114, A1347.	0.6	0
149	Tissue Coexpression of LBP and CD14 mRNA in a Mouse Model of Sepsis. Journal of Surgical Research, 1998, 76, 67-73.	0.8	43
150	Pulmonary LPS-Binding Protein (LBP) Upregulation Following LPS-Mediated Injury. Journal of Surgical Research, 1998, 78, 42-47.	0.8	25
151	CD14 and lipopolysaccharide binding protein expression in a rat model of alcoholic liver disease. American Journal of Pathology, 1998, 152, 841-9.	1.9	72
152	INCREASED EXPRESSION OF INTERFERON-?? IN A RAT MODEL OF CHRONIC INTESTINAL ALLOGRAFT REJECTION1. Transplantation, 1996, 62, 242-248.	0.5	25
153	Induction of lipopolysaccharide-binding protein gene expression in cultured rat pulmonary artery smooth muscle cells by interleukin 1 beta American Journal of Respiratory Cell and Molecular Biology, 1995, 12, 449-454.	1.4	15
154	In Situ localization of specific interferon-Î ³ producing immunocytes within the intestinal wall of chronically rejection rat allografts and the in vitro effect of interferon-Î ³ on intestinal smooth muscle growth. Gastroenterology, 1995, 108, A938.	0.6	0
155	Role of lipopolysaccharide (LPS), interleukin-1, interleukin-6, tumor necrosis factor, and dexamethasone in regulation of LPS-binding protein expression in normal hepatocytes and hepatocytes from LPS-treated rats. Infection and Immunity, 1995, 63, 2435-2442.	1.0	71
156	Lipopolysaccharide Binding Protein Participation in Cellular Activation by LPS. Critical Reviews in Immunology, 1995, 15, 201-214.	1.0	54
157	Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. Gastroenterology, 1989, 97, 255-259.	0.6	309
158	The Quantification of Liver Anatomical Changes and Assessment of Occupant Liver Injury Patterns. , 0,		1